The FreeStyle Libre 3 system sends glucose readings directly to a smartphone every minute. Credit: Abbott.

The US Food and Drug Administration (FDA) has granted clearance to Abbott’s next-generation FreeStyle Libre 3 system for use by diabetic patients aged four years and above.

The new device, which includes a continuous glucose monitoring (CGM) sensor, recorded a 7.9% overall mean absolute relative difference (MARD) and is claimed to be the most accurate 14-day CGM system.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

FreeStyle Libre 3 sends glucose readings directly from the glucose sensor, which is said to be the smallest and thinnest in the world, to a smartphone every minute.

The CGM system also has strong Bluetooth integration, with a range of up to 33ft, which represents a 50% increase on other CGMs.

Abbott stated that the new device will be priced the same as previous versions of the system, in an effort to allow more diabetes patients to benefit from the new technology.

See Also:

The FreeStyle Libre 3 system enables real-time glucose level viewing, glucose history tracking and optional alarms, as well as notifications for serious medical events, such as hypoglycemia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has been approved to pair with the FreeStyle Libre 3 iOS and Android mobile apps.

Abbott diabetes care business senior vice-president Jared Watkin said: “The FreeStyle Libre 3 system is a direct result of listening to our customers – and giving them the innovation and sensing technology they’ve been looking for.

“It’s a game-changer for the millions of people living with diabetes. They’ll be able to manage their health minute-by-minute with the world’s smallest and thinnest sensor and most accurate 14-day CGM system.”

The company stated that the mobile app integrates with the FreeStyle Libre digital ecosystem, including LibreView and LibreLinkUp, to allow caregivers and healthcare professionals to monitor users remotely.

Abbott intends to make the FreeStyle Libre 3 sensor available at participating pharmacies later in the year.